NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT02557217

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Armaron Bio Pty Ltd (from the registry)
Registry
  • NCT NCT02557217
  • ANZCTR ACTRN12615000609550
Other papers using this trial's data
  • Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling After Myocardial Infarction: A Randomized Clinical Trial JAMA cardiology, 2021-07-01 DOI, PubMed 33851966, PMC8047802 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02557217. Randomized; quadruple masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction
Condition
ST Elevation Myocardial Infarction
Intervention (Drug)
NP202
Intervention (Other)
Placebo
Lead sponsor
Armaron Bio Pty Ltd (class: industry)

Record details

Record id
cardio:ct-nct02557217
Content hash
1cd2690efdbb55b4833f467837b8cdcb31c9e2463c1253b665d5b8534f3e1c06